journal article·2018-11-05Open access

Nanosized ethanol based malleable liposomes of cytarabine to accentuate transdermal delivery: formulation optimization, in vitro skin permeation and in vivo bioavailability

Rakesh Raj, Pooja Mongia Raj, Alpana Ram

Abstract

Cytarabine is a pyrimidine nucleoside analog used predominantly for acute myeloid leukemia (AML) and also for other indications, including acute lymphocytic leukemia, chronic myelogenous leukemia, and lymphoma by parenteral route due to its low oral bioavailability. Parenteral administration requires constant plasma level, monitoring for its fluctuation and poor patients compliances. Hence the objective of this work is to construct optimized nanosized malleable liposomes of cytarabine to accentuate transdermal delivery of drug to circumvent previously mentioned drawbacks. We also investigated its characteristics and therapeutic efficiency and attempted to systematically explore the penetration enhancing property. Well characterized ethanolic liposomes were also biologically tested for dermatological safety and systemic bioavailability. Ethanolic liposomes were found to be spherical having nanometric size with low polydispersity and high encapsulation efficiency. Skin permeation and deposition studies revealed significant enhancement. In vivo, skin irritation study of developed formulation showed no erythema or scaling vis-à-vis the liposomes. Blood profile of this novel formulation indicated lower lag time with the high amount of drug within 3-12 h after transdermal administration demonstrating the enhanced percutaneous penetration of cytarabine with no erythema, thus leading to patient's compliance by alternative delivery of drug for the treatment of leukemia.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Advanced Drug Delivery Systems · Bee Products Chemical Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University)

Funding

University Grants Commission

References (39)

Show source-provided references
1. 10.1016/j.clinthera.2009.11.01710.1016/j.clinthera.2009.11.017 ↗
2. 10.1016/S1871-5125(09)34002-910.1016/S1871-5125(09)34002-9 ↗
3. 10.1016/j.addr.2003.10.02810.1016/j.addr.2003.10.028 ↗
4. 10.1016/j.ijpharm.2006.12.00510.1016/j.ijpharm.2006.12.005 ↗
5. 10.1111/j.2042-7158.2012.01535.x10.1111/j.2042-7158.2012.01535.x ↗
6. 10.1016/j.ijpharm.2016.11.01110.1016/j.ijpharm.2016.11.011 ↗
7. 10.1016/j.xphs.2016.10.00110.1016/j.xphs.2016.10.001 ↗
8. 10.1007/s12272-012-0112-010.1007/s12272-012-0112-0 ↗
9. 10.2147/IJN.S8340210.2147/IJN.S83402 ↗
10. 10.3109/10717544.2016.115524410.3109/10717544.2016.1155244 ↗
11. 10.1080/08982104.2016.125424110.1080/08982104.2016.1254241 ↗
12. 10.1016/j.colsurfb.2016.07.02110.1016/j.colsurfb.2016.07.021 ↗
13. Yu Z, Lv H, Han G, et al. Ethosomes loaded with cryptotanshinone for acne treatment through topical gel formulation. PLoS One. 2016;11:e0159967.
14. Wilson V, Siram K, Rajendran S, et al. Development and evaluation offinasteride loaded ethosomes for targeting to the pilosebaceous unit. Artif Cells NanomedBiotechnol. 2017;1–10 [Epub ahead of print].
15. 10.3109/21691401.2015.100850910.3109/21691401.2015.1008509 ↗
16. 10.3109/21691401.2015.104163810.3109/21691401.2015.1041638 ↗
17. 10.3109/21691401.2015.110274210.3109/21691401.2015.1102742 ↗
18. 10.2147/IJN.S13470810.2147/IJN.S134708 ↗
19. 10.3109/03639045.2015.113222710.3109/03639045.2015.1132227 ↗
20. 10.1080/03639045.2017.128771710.1080/03639045.2017.1287717 ↗
21. 10.3109/1061186X.2015.107085510.3109/1061186X.2015.1070855 ↗
22. 10.1016/S0168-3659(99)00222-910.1016/S0168-3659(99)00222-9 ↗
23. 10.1016/j.ejpb.2007.01.02010.1016/j.ejpb.2007.01.020 ↗
24. 10.1016/j.actatropica.2012.06.00410.1016/j.actatropica.2012.06.004 ↗
25. 10.1016/j.ejpb.2004.03.02710.1016/j.ejpb.2004.03.027 ↗
26. 10.1016/j.colsurfb.2014.01.05710.1016/j.colsurfb.2014.01.057 ↗
27. 10.1093/jnci/82.13.110710.1093/jnci/82.13.1107 ↗
28. Draize J, Woodard G, Calvery H. Method for study of irritation and toxicity of substances topically applied to the skin and membranes. J Pharmacol Exp Ther. 1944; 82:377–390.10.1016/S0022-3565(25)08751-8 ↗
29. Guidance for Industry Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. USFDA; 2005:1–30.
30. 10.1016/j.ejps.2016.04.00210.1016/j.ejps.2016.04.002 ↗
31. 10.1016/j.bbamem.2003.11.01610.1016/j.bbamem.2003.11.016 ↗
32. 10.1538/expanim.60.37310.1538/expanim.60.373 ↗
33. Franz TJ, Tojo K, Shah KR, et al. Transdermal delivery. In: Treatise on controlled drug delivery: fundamentals, optimization, applications. Marcel Dekker Inc: New York Bassel and Hong Kong; 1991;341–415.
34. 10.1016/S0163-7827(02)00028-010.1016/S0163-7827(02)00028-0 ↗
35. 10.3109/21691401.2016.114745210.3109/21691401.2016.1147452 ↗
36. 10.1016/j.ejpb.2007.03.00710.1016/j.ejpb.2007.03.007 ↗
37. 10.1016/j.biomaterials.2006.11.01310.1016/j.biomaterials.2006.11.013 ↗
38. 10.1016/j.ejpb.2012.02.00810.1016/j.ejpb.2012.02.008 ↗
39. 10.1111/j.1468-3083.2009.03100.x10.1111/j.1468-3083.2009.03100.x ↗